title: R1--systemic thrombolysis in German stroke units--the experience from the German Stroke data bank.
abstract: BACKGROUND
  Systemic thrombolysis with tissue plasminogen activator (t-PA) for treatment of acute ischemic stroke was approved in Germany in 2000. Up to now, only data from single centers have been available for the study of the use of thrombolysis in a hospital-based approach outside controlled trials. We therefore sought to determine the frequency of application and complications as well as the patient outcome after t-PA treatment in clinical routine of specialized stroke centers in Germany.
  
  
  METHODS
  Within the German Stroke Data Bank Collaboration, 6234 consecutive patients with ischemic stroke were prospectively documented in 20 stroke centers between 1998 and 1999. The patients were centrally followed via telephone interview after 3 months and 1 year to assess global functional outcome using the Modified Rankin Scale.
  
  
  RESULTS
  250 patients (4 %) received systemic t-PA treatment during the study period. The baseline characteristics of these patients were comparable to large clinical trials and phase IV studies. Symptomatic and asymptomatic parenchymal hemorrhage occurred in 22 patients (8.8 %) and was fatal in 3 patients. Follow-up data after 3 months were obtained in 82.4 % of all patients, of which 35 % had a favorable functional outcome (mRS </= 1), while 23.8 % were severely disabled (mRS >/= 4) and 17 % had died.
  
  
  CONCLUSIONS
  The results of our study agree with the assumption that thrombolytic therapy can be performed safely and effectively in daily clinical practice. Nevertheless, the small proportion of patients receiving thrombolysis even in specialized stroke centers calls for further improvement of acute stroke management in Germany.
authors.affiliation: Department of Neurology, Krankenhaus München-Harlaching, Sanatoriumsplatz 2, 81545 Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Schenkel
authors.forename: C
authors.initials: C
authors.lastname: Weimar
authors.forename: T
authors.initials: T
authors.lastname: Knoll
authors.forename: R L
authors.initials: RL
authors.lastname: Haberl
authors.forename: O
authors.initials: O
authors.lastname: Busse
authors.forename: G F
authors.initials: GF
authors.lastname: Hamann
authors.forename: H-C
authors.initials: HC
authors.lastname: Koennecke
authors.forename: H-C
authors.initials: HC
authors.lastname: Diener
mesh_terms: D002543:Cerebral Hemorrhage / Q000473:pathology; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator